Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Price Performance
Novavax stock traded down $3.02 during trading hours on Monday, hitting $57.25. The company had a trading volume of 5,502,091 shares, compared to its average volume of 6,004,275. The firm has a market cap of $4.47 billion, a PE ratio of -3.24, a PEG ratio of 0.06 and a beta of 1.52. Novavax has a one year low of $34.88 and a one year high of $277.80. The firm has a 50-day moving average of $53.79 and a 200 day moving average of $63.64.
Novavax (NASDAQ:NVAX - Get Rating) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.33 by ($0.77). The business had revenue of $703.97 million for the quarter, compared to analyst estimates of $845.20 million. Novavax had a negative return on equity of 572.54% and a negative net margin of 93.91%. The business's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.05) EPS. As a group, research analysts expect that Novavax will post 27.23 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their price target on shares of Novavax from $146.00 to $168.00 in a report on Wednesday, June 8th. Cowen reaffirmed a "buy" rating and issued a $150.00 target price on shares of Novavax in a research note on Friday, June 3rd. Bank of America started coverage on shares of Novavax in a research note on Friday, May 20th. They issued an "underperform" rating and a $35.00 target price for the company. Finally, B. Riley reduced their target price on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Novavax currently has a consensus rating of "Hold" and an average price target of $162.57.